Pulse Biosciences, Inc. (PLSE) 10-K Annual Report March 2017

BURLINGAME, Calif.—(BUSINESS WIRE) – March 14, 2017 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS)

, is hosting an investor conference call today to share information on recent developments and progress for its novel NPS platform in key markets. The Company will also provide financial results for the quarter and year ended December 31, 2016.

Recent Developments

First FDA 510(k) submission for the PulseTx System. The PulseTx is an NPS platform comprised of a tunable nanosecond pulse generator and accompanying tissue applicators. The FDA 510(k) submission is the Company’s first for the PulseTx System and intended to provide a foundation for future submissions for specific indications.

Treatments completed in first dermatologic human pilot study with the Company’s proprietary PulseTx platform. The Company successfully completed patient treatments and follow-up visits in the first PulseTx pilot dose response study with positive interim results. The objective of this first study is to establish safety and tissue response and recovery characteristics of skin to different NPS doses, enabling the Company to identify an initial application in dermatology.

Progress towards entering the clinic with an initial NPS pilot study in immuno-oncology. Pulse Biosciences is pursuing multiple paths for its first pilot study in oncology and expects to initiate first pilot study trial during 2017.

“We are very pleased with our recent progress,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “The submission of our first FDA 510(k) for the PulseTx System and completion of patient treatments and follow-up visits in our dermatology dose response study are significant milestones for the Company.”

Financial Highlights

Cash, cash equivalents, and investments totaled $16.4 million at December 31, 2016 compared to $18.7 million and $3.6 million at September 30, 2016 and December 31, 2015, respectively. The December 2016 balance does not reflect $5.0 million of additional capital raised through the February 2017 private placement of approximately 820,000 shares of the Company’s Common Stock at $6.10 per share. Adjusting for $20.3 million of net proceeds raised in the Company’s second quarter, net cash used during the year totaled $7.5 million.

Operating expenses for fourth quarter ended December 31, 2016 totaled $2.8 million consistent with the $2.8 million reported for the third quarter ended September 30, 2016. Operating expenses for the year ended December 31, 2016 totaled $9.6 million compared to $4.5 million for the year ended December 31, 2015. The operating expenses reported included non-cash charges for stock-based compensation, intangible asset amortization and depreciation totaling $1.6 million for the year ended December 31, 2016 and $1.1 million for the year ended December 31, 2015.

The following information was filed by Pulse Biosciences, Inc. (PLSE) on Tuesday, March 14, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1625101/000162510117000011/plse-20161231x10k.htm

View differences made from one year to another to evaluate Pulse Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Pulse Biosciences, Inc..

Continue

Assess how Pulse Biosciences, Inc.'s management team is paid from their Annual Proxy

Pulse Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Pulse Biosciences, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: PLSE
CIK: 1625101
Form Type: 10-K Annual Report
Accession Number: 0001625101-17-000011
Submitted to the SEC: Mon Mar 20 2017 5:15:28 PM EST
Accepted by the SEC: Mon Mar 20 2017
Period: Saturday, December 31, 2016
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/plse/0001625101-17-000011.htm

Pulse Biosciences, Inc. (PLSE) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

SEC Filings

PLSE Valuations

PLSE Annual Reports

PLSE Quarterly Reports

PLSE Corporate News